As I stated, they created a joint venture with Molson Coors and there was no capital injection of money from Molson into HEXO...the shares of HEXO rose on excitement for a few day after the deal, but then they dropped back down again a few days later after the announcement due the fact that there was nothing substantive gained by HEXO. Molson Coors had approach Aphria first, and Aphria told them to take a hike because there was no investment / injection of capital being offered by HEXO.
Whereas with Canopy and CRON, they received a sizeable injection of capital (in the billions) into their companies, this created an immediate increase in the market capitalization of these firms and translated into a sustained share price increase. Unfortunately for ACB, because they have so many shares outstanding, any kind of capital injection into the company will result in only a small increase to the price of the share (a 2 billion injection into ACB will only result in a $2 per share increase...whereas for a firm like Aphria, that would translate into an $8 a share increase).
ZenMan111, looks like you need to do a little further looking into this story ;)
Market Data 
Markets 
AI
